Passage Bio Inc. Common Stock (PASG)
Stock · NASDAQ · Health Care
$4.52as of 8/28/2026
Price chart
Open in TradingViewActive signals
Support Confirmation87.4%
High Beta25.2%
Support level
$4.44
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
About PASG
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease. The company develops PBML04 for the treatme…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 24
- Website
- www.passagebio.com/
Fundamentals
- 1-day range
- $4.5$4.97
- Market cap
- $14.11M
- P/E (trailing)
- —
- P/E (forward)
- -0.43
- EPS (trailing)
- $-11.84
- Dividend yield
- —
- Beta
- 1.41
- Avg. volume
- 69.3K
52-week range
$3.29$20
Next earnings: March 3, 2026 · EPS estimate $-2.80confirmed
Forecasts
2 analyst ratings
Buy 67%
Hold 33%
Sell 0%
1-year price forecast
High
$23
+408.8%
Median
$15.5
+242.9%
Low
$8
+77.0%
Passage Bio Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- PASGPassage Bio Inc. Common Stock$4.52▲ 4.39%Market cap $14.11MP/E —$3.29$20
- INTSIntensity Therapeutics Inc. Common stock$4.25▲ 0.95%Market cap $11.49MP/E —$3.51$43.5
- JSPRJasper Therapeutics Inc. Common Stock$0.6782▼ 2.98%Market cap $16.98MP/E —$0.3151$2.96
- BCDABioCardia Inc. Common Stock$1.16▼ 0.85%Market cap $10.80MP/E —$0.75$2.29
- CRISCuris Inc. Common Stock$1.49▲ 2.76%Market cap $8.59MP/E —$1.4$39
- AIMAIM ImmunoTech Inc. Common Stock$0.2558▲ 2.32%Market cap $7.51MP/E —$0.1901$2.89
- VIVSVivoSim Labs Inc. Common Stock$0.29▲ 0.00%Market cap $5.53MP/E —$0.2625$5.3
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| PASG Passage Bio Inc. Common Stock | $14.11M | — | $4.52 | ▲ 4.39% | $3.29$20 |
| INTS Intensity Therapeutics Inc. Common stock | $11.49M | — | $4.25 | ▲ 0.95% | $3.51$43.5 |
| JSPR Jasper Therapeutics Inc. Common Stock | $16.98M | — | $0.6782 | ▼ 2.98% | $0.3151$2.96 |
| BCDA BioCardia Inc. Common Stock | $10.80M | — | $1.16 | ▼ 0.85% | $0.75$2.29 |
| CRIS Curis Inc. Common Stock | $8.59M | — | $1.49 | ▲ 2.76% | $1.4$39 |
| AIM AIM ImmunoTech Inc. Common Stock | $7.51M | — | $0.2558 | ▲ 2.32% | $0.1901$2.89 |
| VIVS VivoSim Labs Inc. Common Stock | $5.53M | — | $0.29 | ▲ 0.00% | $0.2625$5.3 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Passage Bio Q2 EPS $(2.44) Beats $(3.47) EstimateBenzinga · 8/10/2026
Insider Activity
Insider Actions →Acquired
136.8K
Disposed
0
- Sondhi Dolan · May 19, 2026 · Grant10.5K
- Derrell Porter · May 19, 2026 · Grant10.5K
- Kapadia Sandip · May 19, 2026 · Grant10.5K
- Athena Countouriotis · May 19, 2026 · Grant10.5K
- Kassberg Thomas Richard · May 19, 2026 · Grant10.5K
- GOWEN MAXINE · May 19, 2026 · Grant10.5K
- Chou William · March 16, 2026 · Grant58.0K
- Borthwick Kathleen · March 16, 2026 · Grant15.6K
Institutional Ownership
March 31, 2026
- Total shares held
- 1.76M
- Total value held
- $13.50M
- Institutional holders
- 32
Top holders this quarter
- Unknown623.7K
- Unknown305.0K
- Unknown133.6K
- Unknown131.6K
- Unknown114.0K
- Unknown86.1K
- Unknown85.3K
- Unknown68.1K
- Unknown41.4K
- Unknown28.6K
See the full, filterable feed with live charts on the MarketWall dashboard.